Skip to main content

Antibody-dependent cellular cytotoxicity (ADCC) assays for functional characterization of mAb

 Antibody-dependent cellular cytotoxicity (ADCC) assays assess the ability of an antibody like nivolumab to recruit immune effector cells, such as natural killer (NK) cells, to target and kill cancer cells. However, nivolumab, an IgG4 monoclonal antibody (mAb), is generally designed to avoid ADCC due to its checkpoint inhibitor function, which is primarily intended to restore T-cell activity rather than direct cytotoxicity. Nevertheless, ADCC assays are still conducted in early drug development to confirm that nivolumab has minimal or no ADCC activity, especially since unintended cytotoxicity could lead to adverse effects.

Principle of ADCC Assay

ADCC occurs when an antibody binds to a target cell, such as a cancer cell, and its Fc region is recognized by Fc receptors (FcγR) on the surface of effector cells like NK cells. When the antibody-coated target cell is brought into proximity with the effector cell, the effector cell becomes activated and releases cytotoxic granules, leading to target cell lysis.

For nivolumab, an ADCC assay would confirm the absence of significant ADCC activity due to its IgG4 backbone, which interacts minimally with FcγR receptors and therefore has reduced cytotoxic potential.

Step-by-Step Procedure for ADCC Assay

  1. Preparation of Target Cells (Cancer Cells)

    • Culture a suitable target cell line that expresses the PD-1 ligand (PD-L1 or PD-L2). Use cell lines relevant to the nivolumab target, such as PD-L1-expressing tumor cells.
    • Label target cells with a fluorescent dye like calcein AM, or with a radioactive marker such as chromium-51 (^51Cr), depending on the detection method. Labeling helps quantify cell lysis by measuring released fluorescence or radioactivity after cell death.

  2. Preparation of Effector Cells (NK Cells)

    • Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors, or use NK-92 cells, which are engineered NK cells that express Fc receptors and are effective in ADCC assays.
    • For optimal results, ensure an effector-to-target (E
      ) cell ratio (commonly 25:1 or 50:1) that provides sufficient sensitivity in detecting any ADCC activity.

  3. Addition of Nivolumab

    • Add nivolumab at various concentrations to the target cells. Include a positive control antibody (such as a therapeutic IgG1 antibody known to induce ADCC) and a negative control (such as an IgG4 isotype control) to validate the assay.
    • Incubate the antibody-target cell mixture briefly to allow nivolumab to bind to the target cells.

  4. Co-Culture of Effector and Target Cells

    • Combine the effector cells with the target cells at the specified E
      ratio.
    • Incubate the co-culture for a specific period, typically 4 hours, to allow interaction and possible cell lysis.

  5. Detection of Target Cell Lysis

    • For fluorescent assays: Measure fluorescence released into the supernatant from lysed cells using a fluorescence plate reader.

    • For radioactive assays: Measure radioactivity in the supernatant, which correlates with the number of lysed cells.

    • Calculate the percentage of specific lysis using the formula:

      Specific Lysis (%)=(Experimental Release - Spontaneous Release)(Maximum Release - Spontaneous Release)×100\text{Specific Lysis (\%)} = \frac{\text{(Experimental Release - Spontaneous Release)}}{\text{(Maximum Release - Spontaneous Release)}} \times 100

  6. Analysis and Interpretation

    • Determine the ADCC activity of nivolumab by comparing it to the positive and negative controls.
    • For nivolumab, minimal to no lysis should be observed, indicating that it does not induce significant ADCC activity due to its IgG4 Fc region. The positive control should demonstrate strong lysis, while the IgG4 isotype control should show minimal ADCC activity.

Key Considerations

  • IgG4 Backbone of Nivolumab: As an IgG4 antibody, nivolumab is engineered to avoid binding strongly to Fcγ receptors, which is reflected in a low ADCC response in this assay.
  • Positive and Negative Controls: Including an IgG1 antibody as a positive control is crucial to verify that the assay system can detect ADCC activity effectively.
  • Effector-to-Target Ratio: The E
    ratio can affect the sensitivity of the assay; higher ratios may yield better sensitivity but should be consistent across replicates.

Summary

This ADCC assay confirms that nivolumab lacks significant ADCC activity, aligning with its primary mechanism of blocking PD-1 to activate T-cells rather than directly mediating cell killing.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more